Status:
ENROLLING_BY_INVITATION
Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part3)
Lead Sponsor:
Osaka Metropolitan University
Collaborating Sponsors:
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
Conditions:
Mpox (Monkeypox)
Eligibility:
All Genders
Brief Summary
The goal of this study is to evaluate the effectiveness of smallpox vaccination administered before the global eradication of smallpox against currently circulating mpox in the Democratic Republic of ...
Detailed Description
Mpox is caused by the monkeypox virus (MPXV), a member of the genus Orthopoxvirus (family Poxviridae). This virus is closely related to the variola virus, which causes smallpox. MPXV was first identif...
Eligibility Criteria
Inclusion
- Individuals born before 1984: Although it is officially stated that smallpox vaccination was administered in the DRC until 1982, individuals born up to 1984 were included to account for potential discrepancies of several years in remote areas.
- Presence of skin lesions suspected to be mpox.
- Provision of informed consent:
- Proxy-assisted informed consent is allowed under safety considerations. Following oral consent, the investigator will document this on the informed consent form as a witness.
Exclusion
- Participants will be excluded from the study under the following conditions:
- • Refusal to participate in the study: Individuals who decline to provide consent for study participation will be excluded.
Key Trial Info
Start Date :
July 31 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2025
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT06984705
Start Date
July 31 2025
End Date
July 31 2025
Last Update
May 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Equateur Provincial Public Health Laboratory
Mbandaka, Équateur Province, Democratic Republic of the Congo